News

The orphan drug designation follows adoption of a positive opinion by the Committee for Orphan Medicinal Products of the European Agency for the Evaluation of Medicinal Products. Orphan

Pharming will now conduct clinical trials to assess the safety and efficacy of its recombinant human C1 inhibitor (rhC1INH) to treat acute attacks of hereditary angioedema (HAE), a

Results from one phase II study conducted in Spain showed that long-term Remune treatment was effective in delaying virologic failure during antiretroviral treatment interruption. The second phase II

As a result, Avanir, through its subsidiary, holds the exclusive worldwide marketing rights to Neurodex for five indications under a royalty-bearing license with the owner of the underlying

The $230 million cash-for-stock transaction is expected to close in the second quarter of 2005, subject to customary closing conditions and regulatory approvals. Following the acquisition, Johnson &

The FDA has approved the company’s license supplement to market the new formulation of its pediatric influenza vaccine – the only influenza vaccine approved for use in children

The Spine-health.com poll of 375 back pain patients who were taking Pfizer’s Celebrex, Bextra, or Merck & Co’s Vioxx shows that only 36% are still taking some brand

The development work will be funded under a $5.6 million grant to Biota from the US National Institutes of Health (NIH). Under the agreement, Aerogen will undertake development

The study, which has enrolled the target of 80 patients, is being conducted at 30 sites in the US, Canada and Puerto Rico. It will compare the effects